Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Bevacizumab 37atezolizumab 25durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 12pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Immunoglobulin G 7regorafenib 6Sorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Yttrium-90 × 90 days × Clear all
NCT05620771 2026-05-26

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Northwestern University

Phase 2 Recruiting
200 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡